EOLS
NASDAQ · Pharmaceuticals
Evolus Inc
$7.05
-0.42 (-5.62%)
Financial Highlights (FY 2026)
Revenue
295.18M
Net Income
-51,292,942
Gross Margin
66.3%
Profit Margin
-17.4%
Rev Growth
+26.0%
D/E Ratio
22.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 66.3% | 66.3% | 33.3% | 33.3% |
| Operating Margin | -11.0% | -9.9% | 33.6% | 33.3% |
| Profit Margin | -17.4% | -16.5% | 27.9% | 24.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 295.18M | 234.29M | 74.40M | 59.96M |
| Gross Profit | 195.79M | 155.40M | 24.80M | 19.98M |
| Operating Income | -32,440,387 | -23,173,544 | 24.98M | 19.96M |
| Net Income | -51,292,942 | -36,640,723 | 20.76M | 14.77M |
| Gross Margin | 66.3% | 66.3% | 33.3% | 33.3% |
| Operating Margin | -11.0% | -9.9% | 33.6% | 33.3% |
| Profit Margin | -17.4% | -16.5% | 27.9% | 24.6% |
| Rev Growth | +26.0% | +26.0% | +16.8% | +10.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 215.91M | 215.91M | 118.48M | 106.32M |
| Total Equity | 9.81M | 9.81M | 131.78M | 117.40M |
| D/E Ratio | 22.00 | 22.00 | 0.90 | 0.91 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -26,209,989 | -19,763,068 | 38.85M | 31.46M |
| Free Cash Flow | — | — | 15.01M | 10.49M |